Melinta Therapeutics to Present Detailed Results from Vabomere TANGO II Trial as well as New In Vitro and In Vivo Findings from Baxdela and Pyrrolocytosine Candidate at ECCMID 2018

NEW HAVEN, Conn., April 16, 2018 (GLOBE NEWSWIRE) — Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today announced that a total of 12 presentations are planned at the upcoming European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) meeting April 21-14, 2018 in Madrid, Spain. Detailed results from the Phase 3 TANGO II study of Vabomere™ (meropenem and vaborbactam) in patients with known or suspected carbapenem-resistant Enterobacteriaceae (CRE) will be presented in a series of six oral and poster presentations.